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INTRODUCTION: 
Molybdenum cofactor deficiency (MoCo) is a rare 
neuro-degenerative condition which is inherited in an 
autosomal recessive pattern. It is characterized by 
neonatal seizures, which often become refractory, 
feeding difficulties, facial dysmorphism, spasticity and 
opisthotonic posturing along with global developmental 
delay and cerebral atrophy. Molybdenum is involved in 
the functioning of four different enzymes including 
sulfite oxidase, aldehyde oxidase, xanthine oxidase, 
and mitochondrial amidoxime reducing component 
(mARC), each harboring the pterin-based molybdenum 
cofactor (MoCo).1 Of these enzymes, sulfite oxidase is 
known to be crucial for neurological functioning. The 
common mutations leading to MoCo deficiency have 
been identified in the genes MOCS1 (type A), MOCS2 
(type B) and rarely GPHN (type C).2 Genetic mutation 
results in the loss of sulfite oxidase activity leading to 
buildup of certain chemicals, including sulfite and 
S-sulfocysteine that causes severe neurologic 
dysfunction in the affected individuals. MoCo deficiency 
also affects the xanthine pathway leading to an 
accumulation of hypoxanthine and xanthine, and low to 
undetectable uric acid levels in blood.3
FIG 1: Molybdenum Cofactor Biosynthesis
Abbreviations: MOCS (Molybdenum Cofactor Synthesis 
Protein), GPHN (Gephyrin Protein)
 
ABSTRACT:
Molybdenum cofactor deficiency is a rare degenerative brain disorder with autosomal recessive inheritance. It presents 
early in neonatal life with seizures, feeding difficulty and spasticity, sometimes misdiagnosed as neonatal hypoxic 
ischemic encephalopathy. Neuroimaging findings are consistent with loss of white matter and volume along with cystic 
encephalomalacic changes. Most of the patients have mutations in the MOCS1 and MOCS2 genes causing imbalance 
in the sulfur-containing amino acid metabolism leading to progressive neurological damage and early childhood death 
in majority of cases. We report a case of a 7 months old child, product of non-consanguineous marriage with history 
of neonatal seizures and global developmental delay. Examination showed facial dysmorphism and spasticity with 
neuroimaging showing marked cortical atrophy and agenesis of corpus callosum.
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CASE REPORT      
A 7 months old boy, product of a non-consanguineous 
marriage but with significant deaths and miscarriages 
on the paternal side, 2nd in order in a family of 2 
siblings, born at term to a healthy mother. There was 
significant antenatal history of mild polyhydramnion 
and brain anomaly was detected on 36 weeks 
gestational scan showing ventriculomegaly. The baby 
had immediate cry and was born with an APGAR score 
of 9 at 1 min and 5 min. Physical examination showed 
normal facies, birth weight of 2.8kg (10th centile), 
length of 51cm (50th centile) and head circumference 
of 33.5cm (10th centile). He was admitted in the 
nursery for four days because of poor suckling and 
multi-focal clonic and tonic seizures. MRI brain on 2nd 
day of life showed severe brain atrophy, agenesis of 
corpus callosum, bilateral symmetical T1W 
hyperintense signals in basal ganglia, cystic 
enlargement in posterior fossa and giant cisterna 
magna. Seizures were controlled with medication 
namely levetiracetam at 40mg/kg/day and child was 
discharged on 5th day of life. At 2nd month of age the 
child developed inconsolable cry, arching episodes and 
opisthotonic posture for which he was started on 
muscle relaxant tizanidine 1 mg/day and clonazepam 
0.2mg/day. At 7 months follow up, child had delayed 
milestones, microcephaly with overriding of sutures, 
facial dysmorphism which was initially not present, 
spasticity in all four limbs and severe muscle wasting. 
On reviewing the family tree, there was death of a 
previous child and multiple miscarriages from the first 
consanguineous marriage of father. Although this child 
was a product of a non-consanguineous marriage, but 
considering the paternal history and early presentation, 
feeding issues, seizures and cerebral atrophy of this 
child, genetic work up was done. 
FIG 2:Cortical atrophy and ventriculomegaly
FIG 3: Bilateral T1W hyperintensities in basal ganglia
FIG 4: Arachnoid cyst (Blue arrow) Agenesis of 
corpus callosum (Green arrow) 
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His whole exome sequencing revealed a missense 
homozygous pathogenic variant in the MOCS2 gene 
causing an amino acid change from Gly to Arg at 
position 76 as shown in Table 1 and genetic diagnosis 
of autosomal recessive Molybdenum cofactor 
deficiency type B was confirmed despite a 
non-consanguineous marriage. His uric acid level was 
low (<1 mg/dl; Range: 2-5mg/dl) which corresponded 
with the disease. At present at the time of case report, 
child is 15 month old, thriving well with weight of 10 kg 
(50th centile), OFC of 47 cm (between 25th – 50th 
centile). He having global developmental delay with no 
gaze fixation or neck holding, poor auditory and feeding 
difficulties. His seizures are well controlled but there is 
spasticity which is also improved. Nature of genetic 
origin has been explained to the family.
TABLE: Results of Genetic Testing
DISCUSSION 
Molybdenum cofactor deficiency is a rare autosomal 
recessive condition of sulfur-containing amino acid 
metabolism. It has an estimated prevalence of 1 in 
100,000 to 200,000 newborns worldwide 4 and nearly 
only 100 cases have been reported in literature.5  It 
classically occurs in early infancy with majority of 
patients presenting with epileptic encephalopathy 
along with feeding difficulties and facial dysmorphism6 
like our index case, although late presentation with 
global developmental delay including motor, visual and 
language impairment7 and atypical presentation with 
movement disorder have also been described.8  Typical 
neuroimaging findings include loss of white matter and 
volume, cystic encephalo-malacic changes and 
ventriculomegaly but novel findings of agenesis of 
corpus callosum and interhemispheric cyst similar to 
our index case have also been reported.3 MoCo 
deficiency has overlapping phenotypic features with 
sulfite oxidase deficiency and is sometimes 
differentiated only biochemically by low serum uric acid 
concentrations due to loss of function of xanthine 
dehydrogenase in MoCo defiency.3 Clinical features can 
also be mistaken for neonatal hypoxic ischemic 
encephalopathy6,9 and children presenting late with 
spastic quadriplegia and intellectual disability are 
usually labelled as cerebral palsy. Treatment with 
exogenous cyclic pyranopterin monophosphate (cPMP) 
for type A deficiency is present.10 Since patients with 
type B deficiency (MOCS2 gene) do not lack this 
molecule, hence they cannot benefit from this 
treatment. However, supplementation with pyridoxine 
could reduce the frequency of seizures in these 
patients.11 The deficiency can also be diagnosed 
prenatally by monitoring the sulfite oxidase activity on 
chorionic villous sampling tissue and subsequent 
mutational analysis can be done.12 Although 
therapeutic options are yet to be ascertained, early 
detection and genetic testing in such degenerating 
brain disorder is important for genetic counselling.13 
Our case report emphasizes that refractory neonatal 
seizures without a clear documented hypoxic ischemic 
event, progressive microcephaly, spasticity and specific 
neuroimaging findings can be clinical clues to early 
diagnosis. Even in the absence of consanguinity, in the 
families where there are unexplained death and 
miscarriages, a high index of suspicion is needed as 
most cases are otherwise labelled as hypoxic ischemic 
encephalopathy and managed as cerebral palsy. Thus, 
a genetic diagnosis is mandatory and important for 
genetic counselling.
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